ART-27.13 is a Small Molecule owned by Artelo Biosciences, and is involved in 3 clinical trials, of which 2 were completed, and 1 is ongoing.
NEO-1940 (AZD-1940) is a mixed CB1/CB2 cannabinoid receptor agonist. Cannabinoid receptors are G-protein coupled receptors. The drug candidate by limiting cell proliferation induces tumour-selective cell death in cancer patients.
The revenue for ART-27.13 is expected to reach a total of $41m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the ART-27.13 NPV Report.
ART-27.13 was originated by AstraZeneca and is currently owned by Artelo Biosciences.
ART-27.13 (NEO-1940, AZD-1940) is under development for the treatment of cancer related anorexia. The drug candidate is an benzimidazole derivative and it is administered orally. It acts on cannabinoid (CB1) type 1 and type 2 receptor. It was also under development for the treatment of post-operative pain, multimodal supportive care in weight loss, appetite loss, pain, nausea, vomiting, anxiety, and insomnia in cancer patients.
Artelo Biosciences Overview
Artelo Biosciences is a biopharmaceutical company. The company develops and commercializes proprietary therapeutics targeting the endocannabinoid system. Artelo Biosciences is a biopharmaceutical company. The company develops and commercializes proprietary therapeutics targeting the endocannabinoid system.
Quick View – ART-27.13
|Highest Development Stage|